OCT-1 as a determinant of response to antileukemic treatment

Abstract

Despite the excellent responses to imatinib therapy observed in patients with chronic phase chronic myeloid leukemia (CP-CML),1 ∼25% of these patients demonstrate primary resistance or suboptimal response. 2 Inadequate inhibition of the kinase activity of BCR-ABL3 due to low intracellular concentrations of imatinib achieved in target leukemic cells has been associated with suboptimal response.4 The organic cation transporter 1 (OCT-1) has been identified as the major active influx pump for imatinib in CML cells,4,5 and has therefore been investigated as a cause of suboptimal response in patients treated with imatinib. © 2011 ASCPT.